BC Extra | Jan 21, 2020
Company News

Horizon gains first FDA approval in thyroid eye disease

With FDA’s approval of Horizon’s thyroid eye disease drug -- the first for the indication -- the company is looking ahead to add to its rare disease pipeline through deal-making. The approval comes ahead of...
BC Extra | Nov 23, 2019
Company News

Nov. 22 Company Quick Takes: AZ’s Btk inhibitor gains expanded approval; plus WuXi Vaccines, SK Bio, ViiV, Horizon and Neon

Label expansion for AZ’s Calquence under Project ORBIS  FDA approved an sNDA for Calquence acalabrutinib from AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat chronic lymphocytic leukemia and small lymphocytic leukemia under the agency’s Real-Time Oncology Review...
BC Innovations | Oct 29, 2019
Distillery Therapeutics

Combined inhibition of G12C-mutant KRAS, mTOR and IGF1R for NSCLC

DISEASE CATEGORY: Cancer INDICATION: Non-small cell lung cancer (NSCLC) Triple therapy with KRAS-G12C, mTOR and IGF1R inhibitors could treat KRAS G12C-mutant NSCLC. Whole genome screening of an shRNA library for targets whose inhibition enhanced the...
BC Extra | Sep 9, 2019
Company News

Sept. 9 Company Quick Takes: Alexion licenses Japanese rights to Eidos candidate; plus Molecular Partners-Allergan, Horizon, Alnylam

Alexion gets Japanese rights to BridgeBio's ATTR therapy  The Eidos Therapeutics Inc. (NASDAQ:EIDX) subsidiary of BridgeBio Pharma Inc. (NASDAQ:BBIO) granted Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) exclusive rights to develop and commercialize transthyretin-mediated amyloidosis (ATTR) candidate AG10...
BC Innovations | Aug 29, 2019
Distillery Techniques

STAT3-based gene signature to predict response to glioblastoma targeted therapy

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling A STAT3-based gene expression signature could identify glioblastoma multiforme (GBM) patients that will respond to STAT3 inhibitors as monotherapies or in combination with IGF1R (insulin-like growth factor-1 receptor; CD221)...
BC Extra | Jul 23, 2019
Clinical News

July 23 Clinical Quick Takes: Achillion plans U.S. IND; plus Chiasma, Myovant, Marinus and Merck

Achillion plans U.S. IND after latest readout for ACH-5228  Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) rose $1.19 (50%) to $3.57 since announcing early Monday that multiple ascending doses of its CFD inhibitor ACH-5228 led to 95% complement...
BC Extra | Mar 7, 2019
Financial News

Follow-on roundup: Horizon, Apellis, Epizyme

Horizon, Apellis and Epizyme each priced follow-ons raising a total of $552 million. Horizon Pharma plc (NASDAQ:HZNP) raised $300 million late Wednesday through the sale of 12 million shares at $24.50. The price is a...
BC Week In Review | Mar 1, 2019
Clinical News

Horizon Phase III teprotumumab data tee up BLA

Horizon Pharma plc (NASDAQ:HZNP) said teprotumumab (HZN-001) met the primary and all secondary endpoints in the Phase III OPTIC trial to treat Graves orbitopathy, also known as thyroid eye disease. The company plans to submit...
BC Extra | Feb 28, 2019
Clinical News

Horizon jumps after teprotumumab data tee up BLA

Horizon Pharma plc (NASDAQ:HZNP) added $7.16 (33%) $29.01 on Thursday after reporting that teprotumumab (HZN-001) met the primary and all secondary endpoints in the Phase III OPTIC trial to treat Graves orbitopathy, also known as...
BC Innovations | Jan 3, 2019
Targets & Mechanisms

Getting kumbaya with infections

Up-and-comer Janelle Ayres is flipping the script on antibiotic resistance with a strategy to convert bacteria from virulent pathogens into benign members of the microbiome and turn infectious diseases into harmless conditions. The idea is...
Items per page:
1 - 10 of 661